Tripp Levy PLLC Announces Investigation of Anadys Pharmaceuticals
17 Ottobre 2011 - 7:48PM
Business Wire
Tripp Levy PLLC, a leading national securities law firm,
announces an investigation into the proposed acquisition of Anadys
Pharmaceuticals, Inc. (NASDAQ: ANDS). Anadys announced that it has
entered into a definitive merger agreement to be acquired by Roche
(SIX: RO, ROG; OTCQX: RHHBY). Under the terms of the merger
agreement, Roche will commence an all cash tender offer for all
outstanding shares of common stock of Anadys at USD 3.70 per
share.
The investigation concerns, among other things, whether the
consideration to be paid to ANDS shareholders is unfair,
inadequate, and substantially below the fair or inherent value.
Indeed, analysts have projected that the true inherent value of
PPDI is at least $4 per share. The investigation further concerns
whether the board of directors of ANDS may have breached their
fiduciary duties by not acting in ANDS shareholders' best interests
in connection with the sale process of ANDS. Indeed, each of
Anadys' directors and executive officers has agreed to tender their
shares in the offer.
If you own ANDS common stock and you wish to discuss this matter
with us, or have any questions concerning your rights and interests
with regard to this matter, please contact
Tripp Levy Tripp Levy PLLC 125 East 82nd Street 9th Floor New York,
New York Toll Free: 877-772-3975
Email: contact@tripplevy.com
Tripp Levy PLLC is a national law firm that specializes in
mergers & acquisitions, takeover litigation, shareholder
rights, and corporate governance matters in state and federal
courts throughout the United States. Attorney advertising. Prior
results do not guarantee a similar outcome.
Grafico Azioni Anadys (NASDAQ:ANDS)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni Anadys (NASDAQ:ANDS)
Storico
Da Giu 2023 a Giu 2024
Notizie in Tempo Reale relative a Anadys Pharmaceuticals (MM) (NASDAQ): 0 articoli recenti
Più Tripp Levy PLLC Articoli Notizie